Skip to content

Clinical Study for Migu Capsule in Improving Clinical symptoms and Pain-Related Cerebral Cortical Activity in Patients With Osteoporosis

Clinical Study for Migu Capsule in Improving Clinical symptoms and Pain-Related Cerebral Cortical Activity in Patients With Osteoporosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025464
Enrollment
Unknown
Registered
2019-08-27
Start date
2019-08-27
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis/back pain

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria of osteoporosis; ? Meet the diagnostic criteria of liver and kidney insufficiency syndrome; ? Women have been menopausal for more than 1 year and aged from 45 to 75 years; ? Have low back pain more than 3 months and VAS scores>=3?; ? Signing of informed consent.

Exclusion criteria

Exclusion criteria: ? Patients with diseases that can cause secondary osteoporosis such as osteomalacia or multiple myeloma, and other diseases that affect bone metabolism. ? Spinal tuberculosis tumor osteomyelitis and other diseases which are difficult to evaluate the effectiveness of drugs. ? Abnormal serum calcium or parathyroid hormone (serum calcium level is higher than the upper limit of normal, and parathyroid hormone (PTH) is 1.5 times higher than the upper limit of normal). ? Patients with severe primary diseases such as epilepsy, severe cardiovascular and cerebrovascular diseases, abnormal liver and kidney functions, hematopoietic system, or serious diseases (such as tumor, etc.) that affect their survival or patients with psychosis. ? Allergic constitution or allergy to multiple drugs or foods or known allergy to research drugs and their ingredients. ? Patients enrolled in other clinical trials within the last month. ? Patients with contraindications to MRI. ? Patients who the researchers considered inappropriate to participate.

Design outcomes

Primary

MeasureTime frame
Pain VAS;functional magnetic resonance imaging;

Secondary

MeasureTime frame
Bone mineral density;TCM score;SF-12;bone metabolic markers;Hospital Anxiety and Depression Scale;Roland-Morris ???????;

Countries

China

Contacts

Public ContactPang Jian

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

lidazul@126.com+86 21 20256519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026